Results of Annual General Meeting

23 Jan 2019

RNS Number : 9033N

Redx Pharma plc

23 January 2019

 

REDX PHARMA PLC

(“Redx” or “the Company”)

Results of Annual General Meeting

Alderley Park, 23 January 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that all resolutions at the Group’s Annual General Meeting, held today, were duly passed.

For further information, please contact:

 

Redx Pharma Plc T: +44 1625 469 920
Lisa Anson, Chief Executive Officer
Dominic Jackson, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)  T: +44 20 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727 1000
Simon Conway/Stephanie Cuthbert

 

About Redx Pharma Plc

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/